Intracerebral Injection of Phospholipase A2 Inhibits Dopamine-mediated Behavior in Rats: Possible Implications for Schizophrenia

Overview

Journal Eur Arch Psychiatry Clin Neurosci

Specialties Neurology
Psychiatry

Date 1995 Jan 1

PMID 8773214

Citations 2

Authors

J Brunner

W F Gattaz

Affiliations

Soon will be listed here.

Abstract

Phospholipase A2 (PLA2) is a key enzyme in the phospholipid metabolism. In the CNS intracellular PLA2 plays an essential role in signal transduction by affecting both dopamine (DA) release and DA-receptor sensitivity. In schizophrenia a disordered phospholipid metabolism and increased activity of PLA2 have been reported. In this study we investigated the effects of intracerebral PLA2 injections on dopaminergic neurotransmission in rats using Ungerstedt's model of rotational behavior. Circling behavior induced by the DA agonist apomorphine after unilateral PLA2 injections into the substantia nigra pars compacta was recorded. Seven and 21 days after intranigral PLA2 injection, apomorphine induced an ipsilateral rotation indicating a long-lasting inhibition of ipsilateral nigrostriatal dopaminergic pathway by PLA2 application. In schizophrenia a reduced dopaminergic activity in the frontal cortex has been hypothesized. Recent spectroscopy studies reported on an accelerated break-down of membrane phospholipids in the frontal cortex from schizophrenics. The present findings suggest that increased PLA2 activity in schizophrenia could accelerate the breakdown of membrane phospholipids and thus contribute to a hypodopaminergy in the frontal cortex of schizophrenic patients.

Citing Articles

Quinacrine and Niclosamide Promote Neurite Growth in Midbrain Dopaminergic Neurons Through the Canonical BMP-Smad Pathway and Protect Against Neurotoxin and α-Synuclein-Induced Neurodegeneration.

Goulding S, Levesque M, Sullivan A, Collins L, OKeeffe G Mol Neurobiol. 2021; 58(7):3405-3416.

PMID: 33713017 DOI: 10.1007/s12035-021-02351-8.

Identification of the Niacin-Blunted Subgroup of Schizophrenia Patients from Mood Disorders and Healthy Individuals in Chinese Population.

Sun L, Yang X, Jiang J, Hu X, Qing Y, Wang D Schizophr Bull. 2017; 44(4):896-907.

PMID: 29077970 PMC: 6007359. DOI: 10.1093/schbul/sbx150.

References

Gattaz W, Schmitt A, Maras A . Increased platelet phospholipase A2 activity in schizophrenia. Schizophr Res. 1995; 16(1):1-6. DOI: 10.1016/0920-9964(94)00060-l. View

Williamson P, Drost D, Stanley J, Carr T, Morrison S, Merskey H . Localized phosphorus 31 magnetic resonance spectroscopy in chronic schizophrenic patients and normal controls. Arch Gen Psychiatry. 1991; 48(6):578. DOI: 10.1001/archpsyc.1991.01810300090013. View

Gattaz W, Kollisch M, Thuren T, Virtanen J, Kinnunen P . Increased plasma phospholipase-A2 activity in schizophrenic patients: reduction after neuroleptic therapy. Biol Psychiatry. 1987; 22(4):421-6. DOI: 10.1016/0006-3223(87)90164-8. View

Anand-Srivastava M, Johnson R . Role of phospholipids in coupling of adenosine and dopamine receptors to striatal adenylate cyclase. J Neurochem. 1981; 36(5):1819-28. DOI: 10.1111/j.1471-4159.1981.tb00436.x. View

Gattaz W, Hubner C, Nevalainen T, Thuren T, Kinnunen P . Increased serum phospholipase A2 activity in schizophrenia: a replication study. Biol Psychiatry. 1990; 28(6):495-501. View

Noponen M, Sanfilipo M, Samanich K, RYER H, Ko G, Angrist B . Elevated PLA2 activity in schizophrenics and other psychiatric patients. Biol Psychiatry. 1993; 34(9):641-9. DOI: 10.1016/0006-3223(93)90157-9. View

Cadet J, Hu M, Jackson-Lewis V . Behavioral and biochemical effects of intranigral injection of phospholipase-A2. Biol Psychiatry. 1989; 26(1):106-10. DOI: 10.1016/0006-3223(89)90013-9. View

Weinberger D . Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry. 1987; 44(7):660-9. DOI: 10.1001/archpsyc.1987.01800190080012. View

Ohmichi M, Hirota K, Koike K, Kadowaki K, Miyake A, Kiyama H . Involvement of extracellular calcium and arachidonate in [3H] dopamine release from rat tuberoinfundibular neurons. Neuroendocrinology. 1989; 50(4):481-7. DOI: 10.1159/000125267. View

10.

Pettegrew J, Keshavan M, Minshew N . 31P nuclear magnetic resonance spectroscopy: neurodevelopment and schizophrenia. Schizophr Bull. 1993; 19(1):35-53. DOI: 10.1093/schbul/19.1.35. View

11.

Bradford P, Marinetti G, Abood L . Stimulation of phospholipase A2 and secretion of catecholamines from brain synaptosomes by potassium and A23187. J Neurochem. 1983; 41(6):1684-93. DOI: 10.1111/j.1471-4159.1983.tb00881.x. View

12.

Ungerstedt U, Arbuthnott G . Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res. 1970; 24(3):485-93. DOI: 10.1016/0006-8993(70)90187-3. View

13.

Olianas M, De Montis G, Concu A, Tagliamonte A, Di Chiara G . Intranigral kainic acid: evidence for nigral non-dopaminergic neurons controlling posture and behavior in a manner opposite to the dopaminergic ones. Eur J Pharmacol. 1978; 49(3):223-32. DOI: 10.1016/0014-2999(78)90097-3. View

14.

Deicken R, Merrin E, Floyd T, Weiner M . Correlation between left frontal phospholipids and Wisconsin Card Sort Test performance in schizophrenia. Schizophr Res. 1995; 14(2):177-81. DOI: 10.1016/0920-9964(94)00036-8. View

15.

Carman L, Gage F, Shults C . Partial lesion of the substantia nigra: relation between extent of lesion and rotational behavior. Brain Res. 1991; 553(2):275-83. DOI: 10.1016/0006-8993(91)90835-j. View

16.

Zetterstrom T, Herrera-Marschitz M, Ungerstedt U . Simultaneous measurement of dopamine release and rotational behaviour in 6-hydroxydopamine denervated rats using intracerebral dialysis. Brain Res. 1986; 376(1):1-7. DOI: 10.1016/0006-8993(86)90893-0. View

17.

Pangerl A, Steudle A, Jaroni H, Rufer R, Gattaz W . Increased platelet membrane lysophosphatidylcholine in schizophrenia. Biol Psychiatry. 1991; 30(8):837-40. DOI: 10.1016/0006-3223(91)90239-i. View

18.

Reid M, Herrera-Marschitz M, Hokfelt T, Lindefors N, Persson H, Ungerstedt U . Striatonigral GABA, dynorphin, substance P and neurokinin A modulation of nigrostriatal dopamine release: evidence for direct regulatory mechanisms. Exp Brain Res. 1990; 82(2):293-303. DOI: 10.1007/BF00231249. View

19.

Oliveira C, Duarte E, Carvalho A . Effect of phospholipase digestion and lysophosphatidylcholine on dopamine receptor binding. J Neurochem. 1984; 43(2):455-65. DOI: 10.1111/j.1471-4159.1984.tb00921.x. View

20.

Di Chiara G, Porceddu M, Morelli M, Mulas M, Gessa G . Substantia nigra as an out-put station for striatal dopaminergic responses: role of a GABA-mediated inhibition of pars reticulata neurons. Naunyn Schmiedebergs Arch Pharmacol. 1979; 306(2):153-9. DOI: 10.1007/BF00498985. View